Publication | Open Access

KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer

Surgical OncologyGastrointestinal OncologyMedicinePembrolizumab MonotherapyGastroenterologyPathologyPd-l1-positive Advanced Gastric/gastroesophagealKeynote-059 Cohort 3Cancer TreatmentOncologyRadiation Oncology